✦ LIBER ✦

Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients

✍ Scribed by T. G. Wreghitt; Simon J. C. Abel; Keith McNeil; Jayan Parameshwar; Susan Stewart; Nat Cary; Linda Sharples; Stephen Large; John Wallwork

Publisher: Springer
Year: 1999
Tongue: English
Weight: 64 KB
Volume: 12
Category: Article
ISSN: 0934-0874
DOI: 10.1007/s001470050219

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ganciclovir prophylaxis after lung and h

Ganciclovir prophylaxis after lung and heart–lung transplantation

✍ M. Halme; I. Lautenschlager; L. Halme; P. Tukiainen; S. Mattila 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 150 KB

Assay of cytomegalovirus susceptibility

Assay of cytomegalovirus susceptibility to ganciclovir in renal and heart transplant recipients

✍ María de Oña Navarro; Santiago Melón; Susana Méndez; Beatriz Iglesias; Ana Palac 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 173 KB

Cyclosporin pharmacokinetics in heart-lu

Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis

✍ V. T. Tsang; A. Johnston; F. Heritier; N. Leaver; M. E. Hodson; M. Yacoub 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 529 KB

Cyclosporin (CsA) is currently the main immunosuppressive agent used in organ transplantation with considerable improvement in graft survival. Oral CsA solution is highly lipophilic, and its bioavailability may be reduced in cystic fibrosis (CF) heart-lung transplant recipients with pancreatic, gas

Lung and heart-lung transplantation in c

Lung and heart-lung transplantation in children

✍ Blakeslee E. Noyes; Geoffrey Kurland; David M. Orenstein 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 910 KB

Valganciclovir for cytomegalovirus proph

Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Robert J. Fontana 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur

Increased incidence of cytomegalovirus i

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis

✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos